Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Nov-Dec;14(6):1613-1615.
doi: 10.1016/j.dsx.2020.08.023. Epub 2020 Aug 26.

Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection

Timotius Ivan Hariyanto  1 , Andree Kurniawan  2
Affiliations
Meta-Analysis

Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection

Timotius Ivan Hariyanto et al. Diabetes Metab Syndr. 2020 Nov-Dec.

Abstract

Background and aims: The coronavirus disease 2019 (COVID-19) number of death cases is still increasing. One of the comorbidities associated with severe outcome and mortality of COVID-19 is dyslipidemia. Statin is one of the drugs which is most commonly used for the treatment of dyslipidemic patients. This study aims to analyze the association between statin use and in-hospital outcomes of COVID-19 infection.

Methods: We systematically searched the Google Scholar database using specific keywords related to our aims until August 1st, 2020. All articles published on COVID-19 and statin were retrieved. Statistical analysis was done using Review Manager 5.4 software.

Results: A total of 9 studies with a total of 3449 patients were included in our analysis. Our meta-analysis showed that statin use did not improve severity outcome [OR 1.64 (95% CI 0.51-5.23), p = 0.41, I2 = 93%, random-effect modelling] nor mortality rate from COVID-19 infection [OR 0.78 (95% CI 0.50-1.21), p = 0.26, I2 = 0%, fixed-effect modelling].

Conclusion: Statin use did not improve in-hospital outcomes of COVID-19 infections. Patients with dyslipidemia should continue taking statin drugs despite COVID-19 infection status, given its beneficial effects on cardiovascular outcomes.

Keywords: COVID-19; Coronavirus disease 2019; Dyslipidemia; Statin; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare no conflict of interest regarding this article.

Figures

Fig. 1
Fig. 1
Forest plot that demonstrates the association of statin use with the severe outcome (A) and mortality rate (B) from COVID-19 infection.
See this image and copyright information in PMC

Comment in

References

    1. Kwenandar F., Japar K.V., Damay V., Hariyanto T.I., Tanaka M., Lugito N.P.H. Coronavirus disease 2019 and cardiovascular system: a narrative review. Int J Cardiol Heart Vasc. 2020;29:100557. doi: 10.1016/j.ijcha.2020.100557. - DOI - PMC - PubMed
    1. Hariyanto T.I., Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020 doi: 10.1016/j.dsx.2020.07.054. 10.1016/j.dsx.2020.07.054. - DOI - PMC - PubMed
    1. Rodrigues-Diez R.R., Tejera-Muñoz A., Marquez-Exposito L., Rayego-Mateos S., Santos Sanchez L., Marchant V. Statins: could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020 doi: 10.1111/bph.15166. 10.1111/bph.15166. - DOI - PMC - PubMed
    1. Reiner Ž., Hatamipour M., Banach M., Pirro M., Al-Rasadi K., Jamialahmadi T. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496. doi: 10.5114/aoms.2020.94655. - DOI - PMC - PubMed
    1. Argenziano M.G., Bruce S.L., Slater C.L., Tiao J.R., Baldwin M.R., Barr R.G. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. doi: 10.1136/bmj.m1996. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances